相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab for the treatment of colorectal cancer
Dahna Coupez et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Guan Wang et al.
NATURE COMMUNICATIONS (2020)
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
Nandakumar Packiriswamy et al.
LEUKEMIA (2020)
Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
Emmanouil Damilakis et al.
CANCERS (2020)
Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer Protocol for an overview of systematic reviews with meta-analyses
Jing Li et al.
MEDICINE (2019)
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
Antonio Marchini et al.
FRONTIERS IN IMMUNOLOGY (2019)
Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy
Huiya Huang et al.
NATURE COMMUNICATIONS (2019)
Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer
Fatma Sena Dost Gunay et al.
CLINICAL COLORECTAL CANCER (2019)
The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability
Yongyun Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Innate immunity to adenovirus: lessons from mice
Svetlana Atasheva et al.
FEBS LETTERS (2019)
Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
Natacha Dencker Trabjerg et al.
CLINICAL CASE REPORTS (2019)
CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment
Jarem Edwards et al.
CLINICAL CANCER RESEARCH (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy
Marie-Claude Bourgeois-Daigneault et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (vol 170, 1109.e1, 2017)
Antoni Ribas et al.
CELL (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng et al.
NATURE REVIEWS CANCER (2018)
Oncolytic Virotherapy: A Contest between Apples and Oranges
Stephen J. Russell et al.
MOLECULAR THERAPY (2017)
Oncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy
Jianhua Chen et al.
ACS NANO (2016)
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
Tuuli Ranki et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Colorectal cancer screening: a global overview of existing programmes
Eline H. Schreuders et al.
GUT (2015)
Immunological Effects of a Tumor Necrosis Factor Alpha-Armed Oncolytic Adenovirus
Mari Hirvinen et al.
HUMAN GENE THERAPY (2015)
MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer
Pedro Nazareth Aguiar et al.
IMMUNOTHERAPY (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
S Varghese et al.
CANCER GENE THERAPY (2006)
分享论文
